Hair Shedding (Telogen Effluvium)

Lookmaxxing · §691

You count the hairs in the drain. You have been counting for six weeks. The version of this you are afraid of — quiet, unfair, on no timeline you agreed to — is almost never what is actually happening. What is happening is a wave of follicles that, two or three months ago, all decided to rest at once after some specific thing your body went through; they are letting go now, on schedule, and another wave is already growing in behind them. The job of this entry is to name what triggered yours, rule out the small list of fixable causes, and give you the realistic timeline back.

Respond · As-needed Evidence Moderate Chapter Lookmaxxing

Most of what looks like going bald is telogen effluvium — a temporary, named, self-resolving condition triggered by something that happened two to three months ago. A single blood panel under two hundred dollars catches the few causes worth fixing (low iron, an under-active thyroid, a sneaky drug). Then time does the rest: shedding slows by month four, density returns by month nine to twelve. The one thing not to do is grab a bottle of biotin — it does nothing for hair you don't already need biotin for, and it quietly distorts the thyroid labs you actually need.

Each follicle on your scalp runs its own clock. It spends two to seven years actively growing a hair (anagen), about two weeks shutting that hair down (catagen), and then about three months resting with the finished club hair still parked in the follicle (telogen). At any moment, around 85 to 90 of every 100 follicles on your head are growing and 10 to 15 are resting, all on slightly offset timers. The resting hair gets pushed out when the next growth phase starts underneath it. That release is your baseline shed — fifty to a hundred hairs a day for a healthy adult Headington 1993.

Telogen effluvium is what happens when something jolts a large fraction of those follicles into rest at the same time. Two or three months later — the length of telogen — they all release on roughly the same schedule. The brush fills up. The shower drain fills up. The hair coming out is not damaged or unhealthy; it is finished and on time. It just happens to be coming out in a clump rather than spread across the next few months Malkud 2015.

One implication that surprises people: the hair you are losing this week was committed to falling out around the time of whatever happened two to three months ago. The shedding is the past arriving on a delay, not the present accelerating.

The list of things that trigger it

The trigger list is short, well-mapped, and almost always recoverable. Cast your mind back to the months before the shedding started and one of these usually fits.

A high fever or a bad illness. Influenza, severe gastroenteritis, anything that put you in bed for days. COVID-19 in particular produced a near-textbook wave of telogen effluvium across early-pandemic cohorts, with the modal onset around eight weeks after symptoms Mieczkowska et al. 2021.
Surgery or general anaesthesia. A documented trigger; even a smooth surgery counts.
A baby. The hormones of pregnancy keep more of your follicles in the growth phase than usual; when they drop at delivery, that whole extra wave moves into rest. Roughly two in five women see visible shedding three to six months postpartum, and effectively all of them see some shift in how their hair grows Lynfield 1960. This is the cleanest natural example of the mechanism and the one that resolves most reliably without doing anything.
Severe psychological stress. Bereavement, divorce, redundancy, sustained burnout. In animal models, the nerve signals around the follicle (substance P, CRH) push hairs into rest under sustained stress; the human evidence is more circumstantial but the trigger-to-shed pattern is real Peters et al. 2006.
Crash dieting. A sustained deficit of more than around 450 calories a day, or a sudden very-low-protein phase, triggers it within a few weeks of starting Rushton 2002. Eating disorders and the aftermath of bariatric surgery are the severe end.
A new drug — or stopping an old one. Retinoids (including isotretinoin), beta-blockers, ACE inhibitors, blood thinners, anticonvulsants, SSRIs and SNRIs, lithium. Stopping the oral contraceptive pill is the same mechanism in reverse Malkud 2015.
Low iron. This one is contested at the edges (more on that below), but a clearly low ferritin in someone with heavy periods or a vegetarian diet is a routine and fixable cause Trost et al. 2006.
A thyroid that's off. Both an under-active and an over-active thyroid produce diffuse shedding. In one series of eighty patients with thyroid dysfunction, roughly four in ten of the hypothyroid group and one in four of the hyperthyroid group had visible diffuse hair loss Vincent & Yogiraj 2013.

Two patterns are worth flagging. First: the iron picture. The intuitive rule — low ferritin causes shedding, replacement fixes it — has a strong mechanistic story and a long clinical tradition. But the biggest case-control study on the question, of 381 women, found no significant ferritin difference between women with chronic shedding and matched controls Olsen et al. 2010. The honest line is: treat genuine deficiency (ferritin under thirty, especially with the matching symptoms — tiredness, breathlessness on stairs, brittle nails), and be sceptical of the "push it over seventy specifically for hair" advice; that target is mechanistically defensible but not proven in a trial.

Second: the thyroid picture is more straightforward. If shedding is happening, get the TSH. If it is off, treat it; the shedding typically normalises along with the rest of the symptoms over a few months.

What to actually do

Two things, in order. Find the cause. Then wait.

The finding part is a tight panel — not a fishing expedition, not a trichology clinic's twenty-tube workup. A primary-care doctor can order all of these, and most are insurance-covered.

Sit with the calendar. Write down the date you first noticed the shedding. Count back 90 days. What was happening then? An illness, a surgery, a baby, a breakup, a new drug, a stopped pill, a punishing diet. The cause is in that window for most people.
Ask for the blood panel: CBC, ferritin, TSH (plus free T4 if TSH is off), and 25(OH)D. Add zinc if your diet has been very restricted. Skip the rest unless something specific points there Mubki et al. 2014.
Try a hair-pull test on yourself: take a small bunch of about sixty hairs near the scalp between your fingers, give a firm but not violent tug. If more than six come away in your hand, it's the active phase of a shed. (Best done on washed but unbrushed hair.)
Photograph your part line from above, in the same light, every two weeks. The mirror will lie to you about whether the density is recovering; the photo will not.

Then the waiting part. Acute telogen effluvium resolves on its own once the trigger has cleared. The shed rate normalises by month four; new hairs are visible as short broken stubble around the hairline by month six; full visible density returns by month nine to twelve Malkud 2015 Hughes & Saleh 2023. Nothing you do will compress that schedule much. The follicle has its own clock.

If you want a backstop — particularly if the shedding has lasted past six months, or if you have an underlying pattern hair loss being unmasked by it — topical minoxidil 5% (foam or solution, twice a day, dry scalp) shortens the resting phase and lengthens the growth phase. It produces a paradoxical extra shed in the first two to eight weeks; that is the mechanism working, not a setback. Low-dose oral minoxidil — under prescription, usually 0.25 to 2.5 mg a day — is the newer move for chronic cases, with a growing case-series base but limited formal trial evidence Perera & Sinclair 2017.

Where labs name a cause — low iron, a thyroid problem, a drug effect — treat that. Iron replacement at the doses your GP prescribes will raise ferritin over three to six months and is appropriate when ferritin is clearly low. Thyroxine replacement (for under-active thyroid) restores both the labs and the hair on the same timeline. Stopping or swapping a culprit drug typically resolves the shed within four months of the switch.

What not to do — especially the biotin thing

The hair-supplement market exists because the shedding feels unbearable and the protocol above is mostly waiting. The honest answer is that almost none of it works on hair you do not already have a deficiency in.

The single most-bought ingredient is biotin, and the case against it is unusually clean. Reviewers found that every documented case of biotin supplementation visibly helping hair was a person who had an actual biotin-deficiency syndrome — a rare condition with other symptoms, not the everyday reader buying a high-street bottle Patel et al. 2017. The harm goes past wasting money: the doses in popular hair supplements (typically 5 to 10 milligrams a day, hundreds to thousands of times the daily requirement) interfere with how labs measure thyroid hormones and the heart-attack marker troponin. People have had missed heart attacks and falsely-normal thyroid panels because of it. The American hair-loss working groups and most clinical labs now ask patients to stop biotin for at least two days before any blood draw Patel et al. 2017.

A few other persistent ones:

"More protein / collagen peptides will fix it." Protein deficiency does produce shedding, but only at the level of sustained severe under-eating Rushton 2002. The well-fed reader gets nothing extra from doubling protein. Collagen peptides have no controlled-trial evidence for hair density at all Guo & Katta 2017.
"I should switch shampoos." Shampoo does not cause this. The shedding is at the level of the follicle, weeks ahead of when the hair surfaces; the wash is just where you notice it.
"I'm going bald." A shed visible enough to terrify you in the shower is almost never visible enough for other people to see. Real telogen effluvium has to push more than around half of your follicles into rest simultaneously to produce obvious thinning, and that is the severe end of severe. The mirror you stare at is calibrated for catastrophe; the part-line photo at week zero versus week eight is not.
"It's androgenetic — I need finasteride." Sometimes true (more often in men), and the two conditions can coexist. But reflex prescribing of pattern-hair-loss drugs to anyone with a shed is a real failure mode. Pattern hair loss is slow, patterned (temples, crown), and produces miniaturised hairs, not bulk shedding. If the timeline fits a recent trigger and the loss is diffuse rather than patterned, this is telogen effluvium, not androgenetic alopecia Mubki et al. 2014.

If you're still shedding at month nine

The protocol above resolves most acute cases inside six months. If you are still shedding at month nine, one of four things is true, and they have different fixes.

The trigger is still there. An unresolved thyroid disorder, ongoing severe stress, or a crash diet that never ended. The body cannot finish a shed cycle while the cause is still active. Re-walk the trigger list with this in mind.
It was misdiagnosed. The most common quiet error is undiagnosed pattern hair loss in someone who also had a transient shed. The shed resolves; the pattern loss is still there, slowly progressing, and looks to the reader like the shedding "never stopped." A dermatologist's trichoscopy distinguishes these cleanly — pattern loss shows miniaturised hairs and reduced density at the crown or temples; pure shedding shows empty follicles and short regrowing hairs uniformly across the scalp Mubki et al. 2014.
It has become chronic. A small fraction of people develop chronic telogen effluvium, in which the shedding persists at a lower level for years before spontaneous remission. Sinclair's longitudinal series of five patients found episodes that lasted from three to eight years, eventually resolving without permanent baldness Sinclair 2005. This is the form low-dose oral minoxidil is increasingly used for.
The labs were distorted. If you were on a high-dose biotin supplement when the bloods were drawn, the thyroid panel in particular may have read normal when it was not. Stop the biotin and retest Patel et al. 2017.

If two of those have been ruled out and the shedding still has not stopped, see a dermatologist rather than another general practitioner. The differential is narrower at that point and the trichoscopy itself is diagnostic.

The timeline back

This is the section to come back to in the bathroom, on the bad mornings.

For acute, single-trigger telogen effluvium with the cause identified and removed:

Weeks one to four after starting. No change. You are still in the active shed. Brushing and washing still produce the count.
Months two to four. The shed rate slows. The visible difference is internal — you stop dreading the shower, because the count starts dropping below where it was at peak. Other people still notice nothing.
Months four to six. Run your hand along your hairline in good light. You start to see short, dark, fine new hairs standing up at an angle — a few centimetres long, perpendicular to the scalp. These are the new growth phase coming through. The part line stops widening Malkud 2015.
Months six to nine. Density visibly increases. The hairdresser notices. A close partner stops carefully not-mentioning it. The new hairs reach blendable length.
Months nine to twelve. You stop thinking about it. The brush comes out close to empty. You catch sight of yourself in a window and the hair is the hair you had before Hughes & Saleh 2023.

That is the median trajectory for the common case. Where iron deficiency is the cause, replacement at the prescribed dose has the shed reduction tracking the rising ferritin over the same three to six month window Trost et al. 2006. Where thyroid disease is the cause, the hair recovery and the rest of the recovery (energy, weight, mood) arrive on the same schedule together Vincent & Yogiraj 2013. Where minoxidil is added, the regrowth curve sits a few weeks earlier and the density at six months is somewhat higher Perera & Sinclair 2017.

There is also a permanent payoff, separate from the hair. Once you have recognised one of these episodes, you will recognise the next one — the late-March shed after a stressful winter, the August shed two months after a bad flu in June — the day it begins, name it the same hour, and not lose the bandwidth you lost the first time. The skill becomes yours.

Related but not this

A few things share the symptom of "more hair coming out than usual" but are different conditions with different management. If your situation does not fit the picture above — sudden patches of total loss, painful scalp, hair coming out from a slow recede at the temples rather than a diffuse thinning — one of these is closer to what you have:

Pattern (androgenetic) hair loss — gradual, patterned at the temples, crown, or central part; produces miniaturised hairs rather than bulk shedding. Slow over years, not weeks. Often overlapping with telogen effluvium in the same person.
Alopecia areata — sudden coin-sized smooth patches of total hair loss. An autoimmune condition with its own treatment path.
Scarring alopecias — frontal fibrosing alopecia, lichen planopilaris, central centrifugal cicatricial alopecia. The follicles are destroyed permanently, so urgency to see a dermatologist is higher.
Traction alopecia — from sustained tight pulling (braids, ponytails, extensions). Hairline-localised; reversible early, permanent late.
Anagen effluvium — the abrupt total shed caused by chemotherapy and a few other cytotoxic exposures. Different mechanism, different timeline Saleh et al. 2023.

Substance and claimed effects

Hair shedding — clinically called telogen effluvium (TE) when above baseline — is the visible loss of scalp hair caused by a synchronised wave of follicles entering the resting (telogen) phase, after which the club hairs fall out roughly two to three months later Headington 1993. Baseline shedding for a healthy scalp is on the order of 50–100 hairs per day; clinically meaningful shedding is typically over 150 per day and is the chief complaint that brings most patients in Malkud 2015 Hughes & Saleh 2023. This entry covers acute and chronic diffuse shedding, its triggers (psychological and physical stress, post-illness, postpartum, weight loss, drugs, iron deficiency, thyroid disease), the standard work-up, the natural course, and what does and does not preserve density. Pattern hair loss (androgenetic alopecia), alopecia areata, and scarring alopecias are out of scope; they share the visible symptom but not the mechanism.

Evidence by addressing question

mechanism

The human scalp carries roughly 100,000 hair follicles, each cycling independently through anagen (active growth, 2–7 years; ~85–90% of follicles at any time), catagen (regression, ~2 weeks; ~1%), and telogen (rest, ~3 months; ~10–15%). The club hair is shed at the end of telogen as a new anagen hair pushes it out — this is the exogen step Headington 1993 Malkud 2015.

Telogen effluvium arises when a stressor abruptly shifts a larger-than-normal fraction of follicles out of anagen and into telogen synchronously. Two to four months later (the duration of telogen), those follicles release their club hairs en masse. Headington described five proposed functional mechanisms, of which the dominant one — immediate anagen release — covers most fever / illness / surgery / psychological-stress / postpartum cases Headington 1993. Delayed anagen release explains postpartum shedding: oestrogen and human placental lactogen prolong anagen during pregnancy; their withdrawal at delivery triggers a synchronous shift into telogen with shedding peaking at 3–6 months postpartum Lynfield 1960. Immediate telogen release (a shortened telogen) is invoked for the rapid shed after starting topical minoxidil. Chronic TE involves a sustained shortening of anagen with persistent low-grade shed and is the substrate for Sinclair's five-patient longitudinal series Sinclair 2005.

The neuro-immune layer: substance P, CRH, and nerve-growth-factor signalling around the follicle drive premature catagen entry under psychoemotional stress in mouse models, with histological evidence of perifollicular neurogenic inflammation; this is the strongest published mechanistic link between psychological stress and shedding, although the leap from murine to human magnitude is still imperfect Peters et al. 2006.

evidence

TE is the most common form of diffuse non-scarring alopecia and is well-characterised at the level of histology (telogen counts on biopsy ≥15–20%, often 25–50% in the active wave), the hair-pull test (≥10% of pulled hairs telogen during active shed), and trichoscopy (empty follicles, regrowing short hairs, predominance of single hairs) Malkud 2015 Mubki et al. 2014. Trigger-association studies show a consistent 2–4 month latency between insult and onset of shed across surgery, high fever, severe febrile illness, crash dieting (≥450 kcal/day deficit), and major psychological events Harrison & Bergfeld 2009 Hughes & Saleh 2023.

For COVID-19, multiple early-pandemic case series found a striking incidence of TE 2–3 months after acute infection; in Mieczkowska's series the modal latency was 58 days from symptom onset Mieczkowska et al. 2021. This is consistent with the classic illness-fever mechanism and has been replicated across many cohorts.

Iron status: this is the most contested association. Trost et al.'s 2006 review concluded that low ferritin (commonly cited threshold 40 ng/mL) is plausibly linked to TE and to female pattern hair loss; many dermatologists target ferritin >70 ng/mL for hair-cycle support Trost et al. 2006 Rushton 2002. The strongest counter-evidence is Olsen et al.'s 2010 case-control study of 381 women, which found no statistically significant difference in ferritin between women with chronic TE, female pattern hair loss, and matched controls — undercutting the routine iron-replacement reflex Olsen et al. 2010. The honest position: deficiency itself (ferritin under ~15, with anaemia) should be corrected for general health reasons and plausibly for hair; the case for borderline-low ferritin as a primary TE driver is weaker than the trichology literature implies.

Thyroid: both hypo- and hyperthyroidism produce diffuse shedding with intermediate latency; Vincent & Yogiraj's series of 80 patients with thyroid dysfunction documented diffuse shedding in 39% of hypothyroid and 28% of hyperthyroid patients, with TE the dominant pattern Vincent & Yogiraj 2013. Thyroxine replacement reverses the shed in months when thyroid was the cause.

Drug-induced TE is well-documented for retinoids, beta-blockers, anticoagulants, ACE inhibitors, anticonvulsants, SSRIs/SNRIs, lithium, and oral contraceptive discontinuation. The latency is the same 2–3 months; reintroducing the drug confirms causality in ambiguous cases Malkud 2015 Mubki et al. 2014.

protocol

The first-line work-up has converged across reviews on a tight panel rather than a fishing expedition: detailed timeline of triggers in the 2–4 months before onset, scalp examination plus hair-pull test (grasp ~60 hairs near the scalp, tug — >10% release is positive), and a focused lab set Mubki et al. 2014 Hughes & Saleh 2023. Labs: CBC, ferritin, TSH (with free T4 if abnormal), 25(OH)D, and where indicated zinc and a basic metabolic panel. ANA and a syphilis serology are reserved for atypical presentations.

Definitive treatment is removal of the trigger plus time. Acute TE self-resolves within 3–6 months once the insult is gone; the hairs that fell are replaced by new anagen hairs that take several more months to reach visible length Malkud 2015 Hughes & Saleh 2023. Topical minoxidil 5% (foam or solution) shortens telogen and prolongs anagen and is used off-label to accelerate recovery and prevent transition to chronic TE; the paradoxical 2–8 week post-initiation shed is a sign of the mechanism, not a treatment failure. Perera & Sinclair's retrospective series of low-dose oral minoxidil (0.25–2.5 mg/day) in chronic TE showed reduction in shed and improvement in patient-reported density, although the study is uncontrolled Perera & Sinclair 2017.

Iron replacement is appropriate when ferritin is genuinely low (commonly <30 ng/mL, especially with menorrhagia or dietary insufficiency); the case for "topping up" a ferritin of 40–60 specifically for hair is mechanistically plausible but not RCT-supported Trost et al. 2006 Olsen et al. 2010.

misconceptions

Biotin. The dominant supplement misconception in this space. Biotin deficiency is genuinely rare (chronic raw-egg-white diet, long-term anticonvulsants, biotinidase deficiency) and produces dermatitis and alopecia that respond to replacement. In the absence of deficiency, biotin supplementation has no demonstrated effect on hair growth; Patel et al.'s 2017 review of 18 reports found that every responder had an underlying biotin-deficiency syndrome Patel et al. 2017. The serious harm — beyond wasted money — is that pharmacologic-dose biotin (the 5–10 mg/day in popular hair supplements) interferes with immunoassays for thyroid hormones, troponin, and others, and has caused missed myocardial infarctions and falsely-normal thyroid panels Patel et al. 2017.

"You're going bald." A wave of shedding from TE rarely produces clinically obvious baldness; widening of the central part or noticeable thinning happens only when over ~50% of follicles enter telogen at once, which is the high end of severity. The reader's perception of clumps is usually accurate about the increased shed but wildly miscalibrated about residual density.

"Just eat more protein / take collagen." Protein deficiency does produce TE, but it requires sustained severe deprivation (calorie restriction, eating disorders, bariatric surgery without supplementation) Rushton 2002 Guo & Katta 2017. The well-nourished reader who switches to a higher-protein diet for hair will not see additional benefit. Collagen peptides have no controlled-trial evidence for hair density.

stakes

Two real stakes. First: the shedding itself is benign and self-limited, but it is a signal. A thyroid disorder, iron deficiency, undiagnosed coeliac disease, or a recent severe illness with sequelae presented through the hair before being diagnosed by labs — TE is occasionally the first noticed symptom of a missed systemic problem Mubki et al. 2014 Vincent & Yogiraj 2013. Second: distress and downstream secondary behaviour. The psychological impact of perceived hair loss is consistently rated severe; readers spend money on unevidenced supplements, defer social activity, and crucially fail to address the actual underlying cause because they are buying biotin instead of getting a TSH Patel et al. 2017.

payoff

Where the trigger is identified and removed, the natural-history payoff is reliable: shed rate normalises by 3–6 months for acute TE; visible density typically returns by 6–12 months, since the regrowing anagen hairs reach the surface around 2–3 months after shed and take additional months to gain visible length Malkud 2015 Hughes & Saleh 2023. For iron-deficiency-mediated cases with severe deficiency, ferritin replacement over 3–6 months consistently correlates with reduced shed; for thyroid-mediated cases, the shed normalises with the TSH Trost et al. 2006 Vincent & Yogiraj 2013. Where minoxidil is added, the recovery curve is faster and density at 6 months higher in the (uncontrolled) series Perera & Sinclair 2017.

failure-modes

The classic failure is the patient who returns at 9 months still shedding — almost always one of: (a) the trigger is still active (untreated thyroid, ongoing severe stress, persistent crash dieting); (b) the shed was misdiagnosed and the patient actually has female pattern hair loss layered on TE, requiring different management; (c) acute TE has transitioned to chronic TE, which by Sinclair's series can persist 3–8 years before spontaneous remission Sinclair 2005; or (d) the patient is taking pharmacologic biotin and the lab panel has been distorted, hiding the real cause Patel et al. 2017. Hair-restoration clinics' default to multi-supplement "hair vitamins" without lab work-up is the institutional version of the same failure.

contraindications

None for the diagnostic workup itself. For minoxidil: pregnancy and breastfeeding are relative contraindications (the topical formulation has limited systemic absorption but the data is thin); low-dose oral minoxidil is contraindicated in uncontrolled hypertension, pheochromocytoma, and renal failure, and should be prescriber-supervised. Iron replacement is contraindicated in hereditary haemochromatosis and should be guided by ferritin and transferrin saturation, not blind Almohanna et al. 2019.

audience

Demographic distribution: women aged 30–60 dominate the clinical population, partly because women notice and present earlier and partly because three of the strongest triggers (postpartum, oral-contraceptive transitions, iron deficiency from menstruation) are sex-specific Malkud 2015. Men experience TE too, particularly after severe illness, weight loss, or psychiatric medication changes; the failure mode in men is misattribution to early androgenetic alopecia and reflex finasteride prescription when the actual driver was an acute insult. Postpartum women are a near-universal case: roughly 40–50% of women experience visible postpartum shed at 2–6 months after delivery, near-100% experience some change in hair-cycle synchronisation Lynfield 1960.

alternatives

Where TE is acute and the trigger has resolved, the alternative to active treatment is observation — and is often the right call. Where it is chronic or persistent, the realistic options beyond minoxidil are limited: low-level laser therapy (modest evidence in androgenetic alopecia, very thin for TE); platelet-rich plasma (similar evidence base; expensive); spironolactone (only for the female-pattern-hair-loss overlap, not for TE itself). Many "hair growth" supplements (Nutrafol, Viviscal) include marine-protein extracts plus a multivitamin; small industry-sponsored trials report modest improvements in shed but independent replication is sparse and the active ingredient unclear Almohanna et al. 2019.

The credibility range

Optimist case

TE is one of the most reassuring diagnoses in dermatology. The pathophysiology is well-mapped, the time course is predictable, the natural history is recovery, and the work-up commonly identifies a fixable underlying issue (low ferritin, occult thyroid disease, drug effect). Standard advice — remove the trigger, correct deficiencies, give it 6 months — works for the large majority of acute cases. Where it does not, minoxidil works as a backstop, and the chronic form, while frustrating, does not progress to baldness. The expected outcome is restored density at the 6–12 month mark; the failure rate of the protocol, when correctly diagnosed and the trigger correctly identified, is low.

Skeptic case

The mechanistic story is cleaner than the empirical work. Olsen et al.'s 2010 finding of no ferritin difference in chronic TE versus controls is a significant rebuke to a large industry recommending iron replacement on borderline numbers Olsen et al. 2010. Many "TE" diagnoses in primary care are actually unrecognised early female pattern hair loss; the shedding complaint is real but the cause is androgenetic, so the standard TE recovery never arrives. Minoxidil's evidence base in TE specifically is far weaker than in AGA — trials are small, uncontrolled, and often funded. The 2–4-month latency rule fails in chronic TE where the trigger is no longer identifiable, leaving "idiopathic" as the diagnosis of exclusion in an embarrassing fraction of cases. Most supplements marketed for hair work primarily because they correct unrecognised deficiencies in a subset; the average reader on the average supplement gets nothing.

Author's call

Acute post-trigger TE is high-evidence and low-controversy: the mechanism is settled, the recovery is reliable, and the protocol — identify and remove trigger, basic labs, time, optional minoxidil — is well-supported. Ferritin is the contested patch; the honest line is to treat genuine deficiency (ferritin under ~30 with symptoms or menstruation) and to be transparent that the "ferritin above 70 for hair" rule is mechanistically defensible but not RCT-proven. Biotin supplementation in the absence of deficiency is the one clear "don't" — it does nothing, costs money, and distorts thyroid and troponin labs. Chronic TE is genuinely frustrating; the article should not promise a quick fix there, and should acknowledge the AGA overlap as the most likely misdiagnosis. Overall: evidence 4, controversy 2.

Stakeholder and incentive map

Trichology clinics and hair-loss centres. Strong commercial incentive to recommend in-house supplements, PRP, and laser therapy; the conservative "remove trigger, wait, get labs" message produces no revenue.
Hair-supplement makers (Nutrafol, Viviscal, biotin brands). Direct-to-consumer marketing has built a multi-billion-dollar market that survives despite weak independent evidence. Patel's review and clinical-lab community work on biotin interference have not dented sales.
Dermatology guideline bodies (AAD, BAD). Generally conservative; emphasise trigger identification and lab work-up; minimal supplement endorsement; AAD has issued warnings about biotin and lab interference.
Trichoscopy and oral-minoxidil practitioners. A growing subspecialty (Sinclair clinic, large social media presence) advancing low-dose oral minoxidil; ahead of the formal guidelines, with growing case-series evidence.
Online communities. /r/tressless and similar — well-informed about pattern hair loss but tend to over-attribute any shed to AGA and push for finasteride, particularly in men.

Population variability

Sex: women dominate the clinical population (2–6× over men in published series), driven by postpartum, OCP-transition, and iron-deficiency triggers. Men are under-presented but not under-affected for the illness, drug, and weight-loss triggers. Age: most common 30–60; pre-pubertal TE exists but is rare. Baseline: hair density and follicle count vary widely (low-density baselines are more conspicuously affected by even normal shed); ethnic variation in hair-cycle parameters is modest but real (Asian hair has the longest anagen, African hair the shortest). Pregnancy / postpartum: a near-universal experience and the cleanest natural model of synchronised telogen release. Co-morbidities: iron deficiency (menstruating women, vegetarians, bariatric patients), thyroid disease (postpartum, autoimmune predisposition), coeliac disease, and inflammatory bowel disease all produce a TE substrate.

Knowledge gaps

The ferritin–TE association is the largest open question; well-powered prospective ferritin-replacement trials in TE (not AGA, not chronic TE) do not exist. Long COVID hair shedding is well-described as TE but the question of whether some cases are mechanistically distinct (persistent immune activation rather than febrile-illness trigger) is unresolved. The split between acute TE and chronic TE — whether chronic TE is a separate entity or a misdiagnosed AGA cohort — is not settled; Sinclair's small longitudinal series remains the canonical reference for the chronic form. Pharmacological-dose biotin supplementation prevalence among presenting patients is poorly tracked despite known lab interference; clinical guidance to "ask about biotin" is recent and uneven. Oral minoxidil at micro-doses is being adopted faster than its formal RCT evidence supports, with safety still tracked primarily through case series.

Scope and the brief. The input description named stress, nutrition and iron status, thyroid function, hormonal shifts, illness recovery, and hair density. All six are covered end to end in the body. Hair density is the framing payoff (the regrowth section is the timeline back to baseline density); the others appear in the trigger list and the protocol.

Excluded by design:

Pattern hair loss (androgenetic alopecia) — different mechanism, different timeline, different management (minoxidil + finasteride / dutasteride / oral minoxidil at different doses). It belongs in its own entry. We flag it twice in this article — as the most common misdiagnosis and as the most common reason an "unresolving shed" is actually still going.
Alopecia areata, scarring alopecias, traction alopecia, anagen effluvium — all listed in out-of-scope. Each warrants its own entry; the framing is "is this you instead?" not "here is how to manage it."
Specific dosing for iron replacement — kept deliberately at the "your GP will prescribe" level. Oral iron protocols (alternate-day dosing, iron gluconate vs sulphate vs bisglycinate, IV infusion thresholds) are clinician territory and should not be self-administered from a catalogue entry.
Specific minoxidil titration for low-dose oral — same reason; this is a prescriber's decision and the safety profile, particularly the cardiac side, needs supervision.

Hard calls during the write:

Ferritin threshold. Trichology consensus pushes "above 70 for hair"; the best case-control data (Olsen et al. 2010) does not support it. We landed on the honest middle — treat genuine deficiency (under ~30 with symptoms), flag the high-target rule as mechanistically defensible but not RCT-proven. This is the controversy=2 we're claiming.
Biotin. Given the catalogue's "field guide" register, we made a stronger anti-recommendation than the AAD's neutral wording, because (a) the evidence is genuinely clean (Patel et al. 2017) and (b) the lab-interference angle moves the action into "actively harmful in the diagnostic phase you are currently in," not just "useless." Worth the editorial firmness.
Dream narrative at sub-40 score. Computed overall ≈33, below the obligatory threshold, but we wrote one in the relief register. The reader of this entry is almost always mid-panic; the entry's natural lever is "this is named, time-limited, and reversible," which is exactly the relief lever the narrative spec describes. The dek and tagline carry it lightly.

Rating difficulties. Energy and short-term health were the hardest calls — both effects are real but mediated through the underlying-cause diagnosis (low iron, sluggish thyroid), not through the shedding itself. We landed on 2 for each because the entry's typical reader actually does often get those gains, just downstream of the workup. Beauty (cumulative) at 3 captures the year-out density restoration in the acute case; we held back from 4 because the entry is a recognition/respond entry, not a daily intervention with built-up effect.

Separate-entry candidates surfaced during writing:

Pattern hair loss (androgenetic alopecia) — the long-form entry. Distinct mechanism, distinct protocol stack.
Ferritin targets for hair — could be its own micro-entry; the debate is substantial enough to merit one.
Low-dose oral minoxidil — the newer protocol with a growing case-series base; would be its own entry once the formal trial evidence catches up.
Biotin and lab interference — overlaps with this entry but is broader (cardiac troponin assays, thyroid panels in general); a screening / labs entry could carry it.
Postpartum hair shedding — could be its own entry if the postnatal cluster grows; covered here as the cleanest example of the mechanism.

Future links: once they exist — androgenetic-alopecia, ferritin-testing, thyroid-screening, minoxidil, postpartum-health.

Category placement. Placed under lookmaxxing because the felt frame is appearance; the body is genuinely medical (workup, drugs, deficiency screening). A future medical placement would also defend; lookmaxxing wins on where readers actually look for this.